Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Draft Guidance Docs Should Be Transitory, Industry Insists

This article was originally published in The Gray Sheet

Executive Summary

Device industry advocates stressed to CDRH during a meeting last week that draft-guidance documents need to more routinely be finalized or withdrawn in an expedited manner, and that agency staffers must resist using the out-for-comment document as if they are settled policy.

You may also be interested in...



Industry Proposes Its FDA Guidance Priorities, Reforms

After FDA published its annual lists of guidance priorities, industry has responded by stating what guidances companies would like to see. Meanwhile, the push for broader reforms to the guidance-development process continues.

CDRH Sets Performance Goals To Reduce Draft Guidance Ambiguity

The device center has committed to metrics for draft guidance documents, trying to address complaints that policies linger too long in the draft stage and create regulatory confusion. CDRH also highlighted recent website upgrades intended to better distinguish between draft and final guidance documents.

Pfizer Says FDA Draft Guidance Is Just Fine; Congress Should Be Patient

In an unusual move, industry rep indicates comfort with draft guidance implementing biosimilar pathway.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT033052

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel